Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma
Overview
- Company: Castle Biosciences, Inc.
- Indication: Stage I Cutaneous Melanoma (CM)
- Drug/test: DecisionDx-Melanoma Test
- Trial Phase: Not Applicable
- NCT ID: Not Available
Background
Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Melanoma patients. The findings were published in the journal Cancers.
Advancement Over Traditional AJCC8
The research demonstrates that the DecisionDx-Melanoma test outperforms the American Joint Committee on Cancer 8th Edition (AJCC8) staging in predicting patient outcomes.
Study Details
The study analyzed survival predictions in a cohort of 5,651 patients from the National Cancer Institute's SEER Program Registries and assessed recurrence and survival in a combined cohort of 1,261 subjects.
Classification System
The DecisionDx-Melanoma test classifies patients into three risk categories: low risk (Class 1A), intermediate risk (Class 1B/2A), and high risk (Class 2B).
Clinical Implications
This gene expression profile test informs patient-specific treatment plans and has been supported by over 50 peer-reviewed publications.
Utilization
As of September 30, 2023, the DecisionDx-Melanoma test has been used in over 146,000 cutaneous melanoma patient evaluations.
Company Profile
Castle Biosciences is dedicated to bringing innovative diagnostic solutions to a range of medical conditions, continually investing in research and development.